期刊文献+

肿瘤特异性T细胞受体转基因T细胞免疫治疗

原文传递
导出
摘要 过继性T细胞免疫治疗已成为一种有效的肿瘤治疗手段,其对于癌灶具有靶向性,单次输注后稳定持续表达使其较单抗类药物更具优越性.T细胞受体(TCR)可特异性识别肿瘤细胞中常见的胞内突变蛋白抗原,使杀伤作用严格限定于肿瘤细胞.恶性肿瘤能通过各种方法来逃避免疫监视,因此很多具有创造性的基因修饰策略被引用于转基因T细胞的研究以促进对肿瘤细胞的特异性识别和杀伤.现对这些策略及其临床实践作一综述.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2014年第11期2641-2642,共2页 Chinese Journal of Experimental Surgery
基金 国家自然科学基金资助项目(81172167)
  • 相关文献

参考文献14

  • 1Mehrotra S,Al-Khami AA,Klarquist J,et al.A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice[J].J Immunol,2012,189 (4):1627-1638.
  • 2Parkhurst MR,Yang JC,Langan RC,et al.T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis[J].Mol Ther,2011,19(3):620-626.
  • 3Klebanoff CA,Gattinoni L,Palmer DC,et al.Determinants of successful CD8 + Tcell adoptive immunotherapy for large established tumors in mice[J].Clin Cancer Res,2011,17(16):5343-5352.
  • 4Yang S,Ji Y,Gattinoni L,et al.Modulating the differentiation status of ex vivocultured anti-tumor T cells using cytokine cocktails[J].Cancer Immunol Immunother,2013,62(4):727-736.
  • 5任鹏,王杰书,郝青,李洪林,卢清军,李国新.T细胞α型趋化因子/CXC趋化因子受体-3生物轴在结肠癌组织中的作用及其意义[J].中华实验外科杂志,2013,30(3):614-614. 被引量:2
  • 6Chinnasamy D,Yu Z,Kerkar SP,et al.Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice[J].Clin Cancer Res,2012,18(6):1672-1683.
  • 7陈树波,李元栋,孔祥顺,姬东辉,宋兰英,孙小芳.1-甲基色氨酸联合树突状细胞疫苗对胰腺癌荷瘤小鼠的免疫作用[J].中华实验外科杂志,2013,30(9):1900-1902. 被引量:3
  • 8薛旦旦,夏添松,刘晓安,查小明,凌立君,王水,肇毅.乳腺癌肿瘤微环境中CD8+T细胞和调节性T细胞的研究[J].中华实验外科杂志,2014,31(1):149-151. 被引量:7
  • 9Topalian SL,Hodi FS,Brahmer JR,et al.Safety,activity,and immune correlates of anti-PD-1 antibody in cancer[J].N Engl J Med,2012,366(26):2443-2454.
  • 10Liu X,Shin N,Koblish HK,et al.Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity[J].Blood,2010,115(17):3520-3530.

二级参考文献26

  • 1王志刚,窦科峰.肿瘤免疫逃逸与转化生长因子-β关系的研究进展[J].中华实验外科杂志,2005,22(4):511-512. 被引量:9
  • 2马向涛,余力伟,王杉,杜如昱,崔志荣.结直肠癌淋巴结转移与趋化因子受体CXCR4/CXCL12信号转导通路的关系[J].中华实验外科杂志,2007,24(1):60-61. 被引量:24
  • 3Itoh K, Yamada A, Mine T,et al. Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol,2009,39:73-80.
  • 4Popov A, Schuhze JL. IDO-expressing regulatory dendritic cells in cancer and chronic infection. J Mol Med (Berl) ,2008,86 : 145-160.
  • 5Davis PM, Nadler SG, Stetsko DK, et al. Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function in- dependent of IDO induction. Clin Immunol,2008,126 : 38-47.
  • 6Lob S, Konigsrainer A. Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction?. Langenbecks Arch Surg, 2008,393:995-1003.
  • 7Muller AJ, DuHadaway JB, Donover PS, et al. Inhibition of indoleam- ine 2,3-dioxygenase, an immunoregulatory target of the cancer sup- pression gene Binl ,potentiates cancer chemotherapy. Nat Med,2005, 11:312-319.
  • 8Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2,3- dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res,2007 ,67 :792-801.
  • 9Belladonna ML, Orabona C, Grohmann U, et al. TGF-beta and kynurenines as the key to infectious tolerance. Trends Mol Med, 2009,15:41-49.
  • 10Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J hnmunother,2006 ,29 :233-240.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部